

## POST MARKETING ADVERSE EVENT REPORT FORM (FOSTER CITY)

GF-21043B (2.0)

<b>Local ID:</b> Gilead MCN: 2015-0184943	3								
DD MMM YYYY  Sex: XMale Female	e Group:	yrs.) Race: Hispanic  Graph Asian  Other (specify)  Weight: 75							
rige at onset of event (yis.)	J J J J	, ·							
Adverse Event (s) or other Safety Information: Adverse Event Description (provide diagnosis, if known)	Start Date (DD/MON/YYYY) Stop Date (DD/MON/YYYY)	(A)Resolved (D)Not resolved (B)Resolved with sequelae (E)Died due to event (C)Resolving (F)Unknown							
1. Lung Cancer	2015/10/31	A □ B □ C □ D □ E 💢 F □							
2.		A B C D E F							
3.		A B C D E F							
4.		A B C D E F							
5.		A							
Did the event(s) result in:  Hospitalization Prolongation of hospitalization Significant disability									
Was the event:  Life threatening (immediate risk of death at time of event)  Fatal (please provide autopsy report)  Date of death://									
Summary of Event(s) / Other Relevant Information:  Please provide a short summary of the event(s) and include any treatment given, relevant medical history, risk factors, outcome, and the results of any supportive laboratory data or other investigations (append results separately, if necessary).									
Patient started treatment 27-08-2015 and discontinued treatment after taking 1 pill of Sovaldi, His death reason was not related to drug he had Lung cancer though there are no additional details in regards of treatment of cancer he was smoker, though we dont have his He had HCV3, his treatment regimen was 24 Weeks Sof+ Rib									
If medical intervention was required to prevent the reported event b reasons.	pecoming serious as defined above,	please check here ☐ and provide							



## POST MARKETING ADVERSE EVENT REPORT FORM (FOSTER CITY)

GF-21043B (2.0)

Medication Details: List all medications (including non-prescri	iption and her	rbal preparation	ns) the patient was re	ceiving at the tim	e of the event(s). Ap	ppend separate sheet, i	if necessary.			
Name	Dose	Route	Start Date (DD/MON/YYYY)	Stop Date (DD/MON/YYYY)	Indication	Lot/Batch No	Suspect <sup>1</sup>	Non- Suspect <sup>2</sup>		
1. Sovaldi	400mg		27-08-201		015	SFMTD		Guopeon		
2. Ribavirin	200mg		27-08-2015 31-10							
3.										
4.										
5.										
6.										
7.										
8.										
<sup>1</sup> Considered to be causally associated with th	ne reported eve	ent(s) <sup>2</sup> Cor	nsidered not to be causa	ally associated with	the reported event(s)	)				
Action taken with Gilea	d Drug	(s):								
Due to the event, was the dosage	of the Gile	ad drug(s):								
☐ Continued unchanged										
If the dose was reduced or drug d	iscontinued	d, did the sy	mptoms:							
Resolve Remain the same										
If the Gilead drug was restarted, did the event reappear?										
□ No □ Y€	es (provide	details):								
Reporter Details:										
Address:				Doctor	Nurse	Pharmacist	Cons	sumer		
			<del></del> -							
				Other, please specify:						
				Preferred method of contact:						
Telephone:				Mail	Fax	Email	Telep	ohone		
Fax:				Other, please specify:						
Email:										
Signature:				Date:		(DD/MON/YYY	Y)			
Gilead Representative	Details	(if applic	cable):							
Name:			·		Responsible Re	egion/Territory:				
Email:	gilead.cor	n		- -						
Telephone:										
Email or FAX Completed	Form as	soon po	ssible to:	or Report by:	Mail:	Gilead Sciences Drug Safety and	•	alth		
Email: Safety FC@gilead.co	<u>m</u>					333 Lakeside Dr	rive.,			
<b>Fax:</b> +1-650-522-5477					Foster City, CA 94404 USA  Telephone: +1-800-445-3235 (USA)					
					Telephone:	T1-000-445-323	o (OOA)			

Please be aware that information provided to Gilead relating to you, may be used to comply with applicable laws and regulations. By providing us with information you are consenting to the control and processing of this personal or sensitive data by Gilead in accordance with applicable data protection laws and the Gilead privacy policy, available to you either on www.gilead.com/privacy or upon request.